Effects of Surface Polarity on the Structure and Magnetic Properties of Co Implanted and Co-Sm Co-Implanted Polar ZnO Films

We present a comprehensive experimental and theoretical study of the effects of surface polarity on the structure and ferromagnetic properties of Co implanted and Co-Sm co-implanted polar ZnO films deposited on sapphire substrates by molecular beam epitaxy. Substantial intrinsic ferromagnetism (FM) is found for all the implanted polar ZnO films. The magnetization of O-polar ZnO is observed to be higher than that of Zn-polar ZnO under the same implantation conditions, and the magnetization is enhanced for Co-Sm co-implanted ZnO in contrast with unimplanted and Co implanted films. First-principles calculations reveal that the Sm 4f and Co 3d states have strong hybridization with the O 2p state in O-polar ZnO, leading to larger magnetic moments for Co and Co-Sm substituting Zn atoms on the O-polar surface. Meanwhile, X-ray photoelectron spectroscopy results confirm that more oxygen vacancies are introduced into O-polar films by implantation and annealing. We consider that the stronger ferromagnetism in O-polar ZnO is associated with the combined influence of more oxygen vacancies and larger local moments related to Co and Sm doping. These results not only contribute to understanding the origin of FM in diluted magnetic semiconductors but also highlight the feasibility of developing polar spintronic devices for future polar thin film systems

Lead Zirconate Titanate Nanowire Textile Nanogenerator for Wearable Energy-Harvesting and Self-Powered Devices

Wearable nanogenerators are of vital importance to portable energy-harvesting and personal electronics. Here we report a method to synthesize a lead zirconate titanate textile in which nanowires are parallel with each other and a procedure to make it into flexible and wearable nanogenerators. The nanogenerator can generate 6 V output voltage and 45 nA output current, which are large enough to power a liquid crystal display and a UV sensor

DataSheet4_Synthesis and Antitumor Activity of Erlotinib Derivatives Linked With 1,2,3-Triazole.zip

Cervical cancer is one of the most important cause of cancer-related death and presents a major public health problem in many countries. To search for more novel antitumor agents against cervical cancer, 14 erlotinib-linked 1,2,3-triazole compounds were designed, synthesized, and evaluated for their anti-tumor activity. The compounds were confirmed by 1H NMR, 13C NMR, and high-resolution mass spectra (HR MS). Antitumor activity assay results indicated that six of those compounds have remarkable inhibitory activity against human cervical cancer HeLa cells in vitro, among which compound 4m was the most potent with IC50 of 3.79 μM, and compounds 4k, 4i, 4l, 4d, and 4n also demonstrated remarkable antitumor activity with IC50 of 3.79, 4.16, 4.36, 7.02, and 8.21 μM. We found three of the most potent compounds 4d, 4k, and 4l induced potent apoptosis and cell cycle arrest in HeLa cells, and compounds 4d and 4l significantly restrained the cell colony formation and showed moderate epidermal growth factor receptor (EGFR) inhibitory activity with IC50 of 13.01 and 1.76 μM. Therefore, these experiments indicate that these erlotinib-linked 1,2,3-triazole compounds are potential to act as effective anticancer agents against cervical cancer.</p

Synergistic Chemo-Photothermal Therapy of Breast Cancer Based on Mesoporous Polydopamine Nanoparticles Decorated with Atovaquone

It remains challenging to develop an effective therapeutic agent for breast cancer. Synergistic therapies, particularly chemo-photothermal therapy, have gained increasing attention in cancer treatment. While the high working temperature achieved in photothermal therapy can kill tumor cells, it also causes thermal damage to nearby healthy cells, limiting the clinical application of chemo-photothermal synergistic therapy. To address these limitations, we have successfully synthesized nanoparticles by combining mesoporous polydopamine with atovaquone (ATO), denoted MPDA-ATO. These nanoparticles (NPs) enable chemo-photothermal therapy to be conducted at a mildly increased temperature of 46 °C. The MPDA-ATO NPs exhibit excellent photothermal stability, potent photothermal conversion properties, and good biocompatibility. In response to near-infrared radiation (NIR), MPDA-ATO can effectively kill 4T1 breast tumor cells in vitro and in the synergistic host. Furthermore, the MPDA-ATO NPs specifically inhibit STAT3, contributing to the antitumor effect. The treatment combining MPDA-ATO NPs with NIR could induce the apoptosis of tumor cells. In summary, the MPDA-ATO NPs offer improved efficacy and safety in treating breast cancer, providing insights and strategies for improved breast cancer therapy

DataSheet3_Synthesis and Antitumor Activity of Erlotinib Derivatives Linked With 1,2,3-Triazole.zip

Cervical cancer is one of the most important cause of cancer-related death and presents a major public health problem in many countries. To search for more novel antitumor agents against cervical cancer, 14 erlotinib-linked 1,2,3-triazole compounds were designed, synthesized, and evaluated for their anti-tumor activity. The compounds were confirmed by 1H NMR, 13C NMR, and high-resolution mass spectra (HR MS). Antitumor activity assay results indicated that six of those compounds have remarkable inhibitory activity against human cervical cancer HeLa cells in vitro, among which compound 4m was the most potent with IC50 of 3.79 μM, and compounds 4k, 4i, 4l, 4d, and 4n also demonstrated remarkable antitumor activity with IC50 of 3.79, 4.16, 4.36, 7.02, and 8.21 μM. We found three of the most potent compounds 4d, 4k, and 4l induced potent apoptosis and cell cycle arrest in HeLa cells, and compounds 4d and 4l significantly restrained the cell colony formation and showed moderate epidermal growth factor receptor (EGFR) inhibitory activity with IC50 of 13.01 and 1.76 μM. Therefore, these experiments indicate that these erlotinib-linked 1,2,3-triazole compounds are potential to act as effective anticancer agents against cervical cancer.</p

DataSheet2_Synthesis and Antitumor Activity of Erlotinib Derivatives Linked With 1,2,3-Triazole.xlsx

Cervical cancer is one of the most important cause of cancer-related death and presents a major public health problem in many countries. To search for more novel antitumor agents against cervical cancer, 14 erlotinib-linked 1,2,3-triazole compounds were designed, synthesized, and evaluated for their anti-tumor activity. The compounds were confirmed by 1H NMR, 13C NMR, and high-resolution mass spectra (HR MS). Antitumor activity assay results indicated that six of those compounds have remarkable inhibitory activity against human cervical cancer HeLa cells in vitro, among which compound 4m was the most potent with IC50 of 3.79 μM, and compounds 4k, 4i, 4l, 4d, and 4n also demonstrated remarkable antitumor activity with IC50 of 3.79, 4.16, 4.36, 7.02, and 8.21 μM. We found three of the most potent compounds 4d, 4k, and 4l induced potent apoptosis and cell cycle arrest in HeLa cells, and compounds 4d and 4l significantly restrained the cell colony formation and showed moderate epidermal growth factor receptor (EGFR) inhibitory activity with IC50 of 13.01 and 1.76 μM. Therefore, these experiments indicate that these erlotinib-linked 1,2,3-triazole compounds are potential to act as effective anticancer agents against cervical cancer.</p

DataSheet1_Synthesis and Antitumor Activity of Erlotinib Derivatives Linked With 1,2,3-Triazole.docx

Cervical cancer is one of the most important cause of cancer-related death and presents a major public health problem in many countries. To search for more novel antitumor agents against cervical cancer, 14 erlotinib-linked 1,2,3-triazole compounds were designed, synthesized, and evaluated for their anti-tumor activity. The compounds were confirmed by 1H NMR, 13C NMR, and high-resolution mass spectra (HR MS). Antitumor activity assay results indicated that six of those compounds have remarkable inhibitory activity against human cervical cancer HeLa cells in vitro, among which compound 4m was the most potent with IC50 of 3.79 μM, and compounds 4k, 4i, 4l, 4d, and 4n also demonstrated remarkable antitumor activity with IC50 of 3.79, 4.16, 4.36, 7.02, and 8.21 μM. We found three of the most potent compounds 4d, 4k, and 4l induced potent apoptosis and cell cycle arrest in HeLa cells, and compounds 4d and 4l significantly restrained the cell colony formation and showed moderate epidermal growth factor receptor (EGFR) inhibitory activity with IC50 of 13.01 and 1.76 μM. Therefore, these experiments indicate that these erlotinib-linked 1,2,3-triazole compounds are potential to act as effective anticancer agents against cervical cancer.</p

Preliminary investigation of the relationship between angiogenesis and growth of E. multilocularis metacestodes and anti-hydatid effect of antiangiogenic agent

Alveolar echinococcosis (AE), caused by Echinococcus multilocularis (E. multilocularis, E.m), is a lethal human parasitosis and always referred to as a tumor-like hydatid disease because of its kind of similarity with tumors in biological features and pathological manifestations. Current primary treatment options for human AE include radical surgery and chemotherapy. For chemotherapy, present licensed anti-human AE chemotherapeutics primarily involve albendazole (ABZ) and mebendazole (MBZ). However, the parasitostatic rather than parasitocidal actions of the agents always lead to a low cure rate and an unavoidable long-term application for AE patients. Thus, new chemotherapeutic agents with high efficacy and low toxicity are urgently needed for the control of echinococcosis. Apatinib, as a novel vascular endothelial growth factor receptor (VEGFR)-targeted therapeutic agent, has been legitimately applied to patients’ terminal cancers and shows encouraging effects. The experiment found that E.m metacestodes appeared active angiogenesis with their growth, indicating a close link between the development and the angiogenesis in AE. As such, in this study we investigated the potential of apatinib as a VEGFR-2 inhibitor against E. m. In addition, the secondary infectious pathway of AE in intermediate hosts remains a controversial issue. The close link between the angiogenesis and the growth and metastasis of E.m metacestodes was demonstrated and the possibility of AE metastasis via lymphohaematogenous pathway was verified. The preliminary in vitro experiment also showed that apatinib could dose-dependently eradicate E.m- PSCx. No significant cytotoxicity at an effective anti-E.m-PSCx concentration of the drug was exhibited

Table4_Discovery of a Series of 1,2,3-Triazole-Containing Erlotinib Derivatives With Potent Anti-Tumor Activities Against Non-Small Cell Lung Cancer.XLS

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are emerging at the vanguard of therapy for non-small-cell lung cancer (NSCLC) patients with EGFR-activating mutations. However, the increasing therapeutic resistance caused by novel mutations or activated bypass pathways has impaired their performance. In this study, we link one of the commercial EGFR-TKIs, Erlotinib, to different azide compounds to synthesize a novel class of 1,2,3-triazole ring-containing Erlotinib derivatives. We discovered that several new compounds show robust antiproliferation activity against diverse NSCLC cells in vitro including PC-9, H460, H1975 and A549. Two of the most potent compounds, e4 and e12 have been found to be more efficient than Erlotinib in all NSCLC cell lines except PC-9. They significantly induce apoptosis and cell cycle arrest in PC-9 and H460 cells. The antitumor efficacy of compound e4 in vivo is close to that of Erlotinib in a PC-9 xenograft mouse model. Most Erlotinib-1,2,3-triazole compounds exhibit moderate to good inhibitory activities toward wild-type EGFR as indicated by enzyme-linked immunosorbent assay (ELISA), and the EGFR phosphorylation was inhibited in H460 and PC-9 cells exposed to e4 or e12. These data suggest that these Erlotinib-1,2,3-triazole compounds are suitable candidates for use against NSCLC and more unknown mechanisms merit further investigation.</p

DataSheet2_RNA-Seq Based Toxicity Analysis of Mesoporous Polydopamine Nanoparticles in Mice Following Different Exposure Routes.xlsx

Mesoporous polydopamine nanoparticles (MPDA NPs) are promising nanomaterials that have the prospect of clinical application for multi-strategy antitumor therapy, while the biosecurity of MPDA NPs remains indistinct. Here, transcriptome sequencing (RNA-Seq) was performed to systematically reveal the toxicity of MPDA NPs to five categories of organs after three different exposure routes, including intravenous injection, intramuscular injection, and intragastric administration. Our results uncovered that MPDA NPs could be deposited in various organs in small amounts after intravenous administration, not for the other two exposure routes. The number of differentially expressed genes (DEGs) identified in the heart, liver, spleen, lung, and kidney from the intragastric administration group was from 22 to 519. Similarly, the corresponding number was from 23 to 64 for the intramuscular injection group and was from 11 to 153 for the intravenous injection group. Functional enrichment analyses showed 6, 39, and 4 GO terms enriched for DEGs in intragastric administration, intramuscular injection, and intravenous injection groups, respectively. One enriched pathway was revealed in intragastric administration group, while no enriched pathway was found in other groups. Our results indicated that MPDA NPs produced only slight changes at the transcriptome level in mice, which provided new insights for further clinical application of MPDA NPs.</p